Endocrine Disrupting Chemicals in EU Cosmetics: What Regulation 1223/2009 Requires in 2026

Oxybenzone appeared in roughly 70% of European sunscreen formulations a decade ago. Today, brands are scrambling to reformulate — not because their own safety data changed, but because the EU’s evolving approach to endocrine disrupting chemicals is systematically working through the UV filter annexes of Regulation (EC) No 1223/2009. The EU’s Scientific Committee on Consumer Safety has flagged oxybenzone, homosalate, benzophenone-1, and a growing list of preservatives for potential EDC properties. And the way the EU handles these findings is not subtle: once an adverse opinion lands, reformulation stops being optional. The question is when, not whether.

For cosmetics brands selling in the EU, this is a compliance dynamic worth understanding precisely — not because the restrictions are arriving tomorrow, but because the lag between an SCCS opinion and an active ingredient removal typically spans three to five years, and reformulating around a core UV filter or load-bearing preservative is rarely a six-month project.

Why the EU’s Hazard-Based Approach to EDCs Is Fundamentally Different

The root of this issue is a philosophical divide between regulatory systems. The US FDA uses a risk-based framework: a substance is evaluated on whether it poses meaningful risk at the concentrations actually used in a finished product. The EU, for an expanding category of substances, uses a hazard-based approach — if an ingredient demonstrates endocrine disrupting properties in the scientific literature, the level of consumer exposure becomes largely irrelevant to the question of whether it belongs in a cosmetic product.

This distinction has real consequences for formulators. A preservative or UV filter that clears FDA scrutiny for a US OTC product may face restriction under Regulation 1223/2009, not because of new toxicity findings at the doses used, but because the EU’s evaluation criteria have shifted. The EU Chemical Strategy for Sustainability, published in October 2020, committed explicitly to treating EDCs in consumer products — cosmetics included — with the same precautionary weight applied to carcinogens, mutagens, and reproductive toxicants. Article 15 of Regulation (EC) No 1223/2009 already prohibits confirmed CMR category 1A and 1B substances without exception. The direction of travel is clear: EDCs are being pulled toward the same treatment.

It’s worth being precise about what “hazard-based” means in practice. It doesn’t mean every ingredient with a single published study showing hormonal activity gets immediately banned. The SCCS evaluates a weight of evidence — in vitro data, animal studies, mechanistic information, and where available, human exposure data. But the threshold for triggering restrictions is lower than the FDA’s, and once an ingredient is flagged as an EDC, the burden shifts. Manufacturers can no longer simply argue that the dose makes the poison.

Which Ingredients Are Under Active SCCS Scrutiny

Homosalate is the clearest case study of where this process leads. The SCCS concluded that homosalate is not safe at concentrations above 0.5% — a finding that effectively rendered the ingredient non-functional at the 10% levels commonly used to achieve SPF30 and SPF50 performance in European sunscreens. The Commission introduced restrictions based on that opinion, and further tightening tied to homosalate’s confirmed EDC profile remains on the regulatory agenda. Brands that hadn’t begun reformulating when the draft opinion first circulated found themselves facing a compressed timeline for new stability data, revised cosmetic product safety reports, and fresh preservative efficacy testing.

Benzophenone-3 (oxybenzone) is under similar pressure. The current EU framework permits it at 6% in face products and 0.5% in body lotions under Annex VI of 1223/2009. The SCCS has reviewed its systemic absorption data and raised concerns about both its photoallergenic profile and potential hormonal activity. The Commission’s dossier on oxybenzone continues to move through the regulatory process, but several European brands have already shifted to avobenzone-stabilised or Tinosorb-based formulas rather than waiting on an outcome they consider likely to tighten further.

Triclosan illustrates how permitted uses can erode gradually. Already restricted in EU cosmetics to 0.3% in toothpaste and 0.2% in certain rinse-off product categories under Annex V, it remains under continued review for its thyroid-disrupting properties. What the current SCCS assessment ultimately means for those remaining permitted uses is unresolved. But for any brand that relies on triclosan’s preservative function, treating those approved uses as borrowed time is the prudent position.

Parabens are the older precedent that explains the current dynamic most clearly. Propylparaben and butylparaben were restricted in 2014 to a maximum of 0.14% (as acid) individually, and prohibited entirely in products for children under 3 applied to the nappy area — restrictions driven by endocrine disruption concerns rather than acute toxicity data. The hazard-based logic applied to parabens in 2014 is now being applied, with the same structural approach, to UV filters. Brands that learned from the paraben transition — building genuine flexibility into their preservation systems and UV protection strategies — are better positioned to absorb the next round.

How the Annex System Translates to Actual Product Timelines

Understanding the mechanics of Regulation (EC) No 1223/2009 helps brands map their exposure accurately. The Regulation operates through a series of annexes:

• Annex II: Substances prohibited in cosmetic products (approximately 1,350 entries)
• Annex III: Restricted substances permitted only under specified conditions of use
• Annex V: Authorised preservatives with defined maximum concentrations
• Annex VI: Authorised UV filters with defined maximum concentrations

An ingredient flagged for EDC properties doesn’t vanish from product formulas overnight. The typical sequence runs: Commission mandate to SCCS → SCCS scientific evaluation (24 to 48 months) → published opinion → Commission drafts an amendment → Member State consultation → publication in the Official Journal → transition period (usually 12 to 18 months). That full process spans three to five years in most cases.

Here’s where brands routinely miscalculate. Reformulating a UV filter — especially one that’s load-bearing for SPF performance — isn’t a label swap. It requires a new stability programme (typically 12 months’ real-time and accelerated data), a revised CPSR prepared by a qualified safety assessor, and frequently new challenge testing under ISO 11930 if the preservation system also changes. In practice, completing a reformulation cycle that maintains marketing claims and satisfies regulatory review takes 18 to 24 months under favourable conditions. An independent stability programme for a single SKU variant runs approximately €4,000 to €12,000 depending on the testing protocol and lab. Starting that work 18 months before a restriction takes legal effect is not early — it’s barely adequate.

There’s also an emergency mechanism worth knowing. Article 31 of Regulation 1223/2009 allows the Commission to adopt provisional measures when a substance poses an urgent risk to human health, compressing what would normally be a multi-year legislative process to as little as 70 days. Article 31 has been used sparingly, but brands with meaningful product exposure to any ingredient under urgent SCCS review should not assume the standard timeline applies to them.

The Export Complication — EU, FDA, and Health Canada Are Not in Sync

For European brands with US or Canadian distribution, the regulatory divergence adds a genuine product management dimension that’s easy to underestimate. Oxybenzone (benzophenone-3) remains an approved active ingredient in OTC sunscreens in the US under 21 CFR Part 352 at concentrations up to 6%. Health Canada permits it in sunscreens at the same level. An EU-compliant reformulation that replaces BP-3 with Tinosorb S or Tinosorb M — filters permitted in the EU under Annex VI — runs immediately into problems in North America: neither Tinosorb filter is approved by the FDA for use in OTC sunscreen products, and the FDA’s sunscreen monograph has been a slow-moving regulatory project for well over a decade.

The practical consequence is that mid-sized European cosmetics brands frequently find themselves maintaining entirely separate formulas for EU and North American markets — not as a deliberate strategic choice, but as a compliance necessity. That means separate stability profiles, separate CPSRs or equivalent safety assessments, separate manufacturing protocols, and in some cases separate manufacturing runs. For brands producing at scale, the complexity is manageable with the right infrastructure. For brands in the €5M to €20M revenue range entering North American distribution for the first time, discovering the formula bifurcation requirement mid-launch is a serious and expensive setback.

The cleanest way to avoid that scenario is to build multi-market regulatory mapping into product development before the formula is finalised — not after it’s three months into stability. That means knowing, at the ingredient selection stage, which UV filters and preservatives are permitted in every target market, and which are under current SCCS review or FDA assessment. We work through exactly this kind of cross-jurisdictional ingredient mapping with European brands at the earliest stages of development, because retrofitting compliance is always more expensive than building it in.

Start the Ingredient Review Now — The Window Is Real but Finite

The most actionable step European cosmetics brands can take right now is a structured ingredient-level review: map every UV filter and preservative in the portfolio against current SCCS opinion status. Several opinions published between 2020 and 2024 have not yet translated into Commission amendments — which means there’s still a working window for orderly reformulation. But that window closes without notice. Once an amendment enters the Commission’s formal legislative drafting process, the transition period becomes the only remaining buffer, and that buffer has to cover your entire development and stability timeline.

Regulation 1223/2009 compliance has always required forward-looking ingredient surveillance. In 2026, with the EU’s Chemical Strategy for Sustainability in full implementation and the SCCS EDC review pipeline running at pace, that surveillance is not a background task. It’s the foundation of a durable market access strategy.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe. Learn more about our team

Talk to our team about EU market entry. Contact us

Related from our network

• ISO 17025-Accredited Cosmetic and Sunscreen Testing for Export — Qalitex Laboratories supports EU cosmetics brands with US-market SPF testing, stability programmes, and safety assessments under FDA OTC requirements.
• Health Canada Cosmetics Compliance for European Brands — Androxa provides Canadian regulatory testing and compliance support, including sunscreen active ingredient assessments under Health Canada’s framework.